 NuCana trades at a bit more than half its cash position as a result of a March 2022 sell-off, caused by the trial discontinuation of the furthest-advanced drug candidate. The companys current drug candidates, NUC-3373 and NUC-7738, show remarkable results across different solid tumors, either substantially improving chemotherapy or creating novel treatment. 